Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to dep… Read more
Market Cap & Net Worth: Kairos Pharma, Ltd. (KAPA)
Kairos Pharma, Ltd. (NYSE MKT:KAPA) has a market capitalization of $12.95 Million ($12.95 Million) as of March 19, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #29821 globally and #9860 in its home market, demonstrating a 11.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kairos Pharma, Ltd.'s stock price $0.62 by its total outstanding shares 20743765 (20.74 Million).
Kairos Pharma, Ltd. Market Cap History: 2024 to 2026
Kairos Pharma, Ltd.'s market capitalization history from 2024 to 2026. Data shows growth from $31.53 Million to $12.61 Million (0.00% CAGR).
Kairos Pharma, Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kairos Pharma, Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KAPA by Market Capitalization
Companies near Kairos Pharma, Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Kairos Pharma, Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Kairos Pharma, Ltd. Historical Marketcap From 2024 to 2026
Between 2024 and today, Kairos Pharma, Ltd.'s market cap moved from $31.53 Million to $ 12.61 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.61 Million | -14.37% |
| 2025 | $14.73 Million | -53.29% |
| 2024 | $31.53 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 4th, 2026 the market cap of Kairos Pharma, Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.95 Million USD |
| MoneyControl | $12.95 Million USD |
| MarketWatch | $12.95 Million USD |
| marketcap.company | $12.95 Million USD |
| Reuters | $12.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.